These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11477311)

  • 21. The efficacy of mycophenolate mofetil treatment in the prevention of acute renal rejection is related to plasma level of mycophenolic acid.
    Kuriata-Kordek M; Boratyńska M; Klinger M; Woźniak M; Urbaniak J; Szyber P; Patrzalek D; Tupka D
    Transplant Proc; 2002 Nov; 34(7):2985-7. PubMed ID: 12431678
    [No Abstract]   [Full Text] [Related]  

  • 22. [A new immunosuppressor: CellCept].
    Mouly-Bandini A
    Presse Med; 2001 Jan; 30(2):66-7. PubMed ID: 11244816
    [No Abstract]   [Full Text] [Related]  

  • 23. [Immunosuppressive drug monitoring of cyclosporine, tacrolimus, and mycophenolate mofetil in renal transplantation].
    Uchida K
    Nihon Jinzo Gakkai Shi; 2005; 47(4):423-9. PubMed ID: 15971884
    [No Abstract]   [Full Text] [Related]  

  • 24. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring.
    Holt DW; Armstrong VW; Griesmacher A; Morris RG; Napoli KL; Shaw LM; ; ;
    Ther Drug Monit; 2002 Feb; 24(1):59-67. PubMed ID: 11805724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate mofetil for transplantation: new drug, old problems?
    Gray DW
    Lancet; 1995 Aug; 346(8972):390. PubMed ID: 7623565
    [No Abstract]   [Full Text] [Related]  

  • 26. High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection.
    Kahan BD
    Transplant Proc; 1998 Aug; 30(5):1639-41. PubMed ID: 9723224
    [No Abstract]   [Full Text] [Related]  

  • 27. Mycophenolate mofetil: a decade of clinical experience.
    Danovitch GM
    Transplantation; 2005 Oct; 80(2 Suppl):S272-4. PubMed ID: 16251860
    [No Abstract]   [Full Text] [Related]  

  • 28. Therapeutic drug monitoring of mycophenolate mofetil in transplantation.
    van Gelder T; Le Meur Y; Shaw LM; Oellerich M; DeNofrio D; Holt C; Holt DW; Kaplan B; Kuypers D; Meiser B; Toenshoff B; Mamelok RD
    Ther Drug Monit; 2006 Apr; 28(2):145-54. PubMed ID: 16628123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive activity of mycophenolate mofetil.
    Eugui EM; Allison AC
    Ann N Y Acad Sci; 1993 Jun; 685():309-29. PubMed ID: 8363235
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.
    Shaw LM; Korecka M; DeNofrio D; Brayman KL
    Clin Biochem; 2001 Feb; 34(1):17-22. PubMed ID: 11239510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring of mycophenolic acid in pediatric renal transplant recipients.
    Armstrong VW; Shipkova M; Schütz E; Weber L; Tönshoff B; Oellerich M;
    Transplant Proc; 2001; 33(1-2):1040-3. PubMed ID: 11267182
    [No Abstract]   [Full Text] [Related]  

  • 32. Mycophenolate mofetil pharmacodynamics and pharmacokinetics correlate with rejection score in a BN-to-LEW heterotopic heart transplant model.
    Klupp J; van Gelder T; Dambrin C; Regieli J; Boeke K; Billingham ME; Morris RE
    Transplant Proc; 2001 May; 33(3):2170-1. PubMed ID: 11377490
    [No Abstract]   [Full Text] [Related]  

  • 33. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels.
    Meiser BM; Pfeiffer M; Schmidt D; Ueberfuhr P; Reichenspurner H; Paulus D; von Scheidt W; Kreuzer E; Seidel D; Reichart B
    Transplant Proc; 1999; 31(1-2):84-7. PubMed ID: 10083018
    [No Abstract]   [Full Text] [Related]  

  • 34. Mycophenolate mofetil--a new immunosuppressant for organ transplantation.
    Med Lett Drugs Ther; 1995 Sep; 37(958):84-6. PubMed ID: 7674993
    [No Abstract]   [Full Text] [Related]  

  • 35. PharmGKB summary: mycophenolic acid pathway.
    Lamba V; Sangkuhl K; Sanghavi K; Fish A; Altman RB; Klein TE
    Pharmacogenet Genomics; 2014 Jan; 24(1):73-9. PubMed ID: 24220207
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Oellerich M; Shipkova M; Schütz E; Wieland E; Weber L; Tönshoff B; Armstrong VW
    Ther Drug Monit; 2000 Feb; 22(1):20-6. PubMed ID: 10688252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mycophenolate mofetil in renal transplantation].
    Uchida K
    Nihon Rinsho; 2005 May; 63 Suppl 5():684-91. PubMed ID: 15954430
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites.
    Schütz E; Shipkova M; Armstrong VW; Niedmann PD; Weber L; Tönshoff B; Pethig K; Wahlers T; Braun F; Ringe B; Oellerich M
    Transplant Proc; 1998 Jun; 30(4):1185-7. PubMed ID: 9636479
    [No Abstract]   [Full Text] [Related]  

  • 39. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
    Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
    Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
    [No Abstract]   [Full Text] [Related]  

  • 40. Mycophenolate: better value through monitoring?
    Tredger JM; Brown NW
    Transplantation; 2006 Feb; 81(4):507-8. PubMed ID: 16495794
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.